Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine

被引：11

作者：

Winokur, Patricia L. ^{[1
,2
]}

Patel, Shital M. ^{[3
,4
]}

Brady, Rebecca ^{[5
]}

Chen, Wilbur H. ^{[6
]}

El-Kamary, Samer S. ^{[6
]}

Edwards, Kathryn ^{[8
]}

Creech, C. Buddy ^{[8
]}

Frey, Sharon

Keitel, Wendy A. ^{[4
]}

Belshe, Robert ^{[9
]}

Walter, Emmanuel ^{[10
]}

Bellamy, Abbie ^{[7
]}

Hill, Heather ^{[7
]}

机构：

[1] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA

[2] Iowa City VA Healthcare Syst, Iowa City, IA USA

[3] Baylor Coll Med, Dept Med, Houston, TX 77030 USA

[4] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA

[5] Cincinnati Childrens Hosp, Gamble Program Clin Studies, Cincinnati, OH USA

[6] Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA

[7] EMMES Corp, Rockville, MD USA

[8] Vanderbilt Univ, Dept Pediat, Nashville, TN 37235 USA

[9] St Louis Univ, Dept Internal Med, St Louis, MO 63103 USA

[10] Duke Univ, Sch Med, Dept Pediat, Durham, NC USA

来源：

JOURNAL OF INFECTIOUS DISEASES | 2015年 / 212卷 / 04期

基金：

美国国家卫生研究院;

关键词：

H5N1; influenza; vaccine; prime-boost; MEMORY B-CELLS; PANDEMIC INFLUENZA; ANTIGENIC VARIANT; HUMANS;

D O I：

10.1093/infdis/jiv087

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Influenza A(H5N1) vaccination strategies that improve the speed of the immunological response and cross-clade protection are desired. We compared the immunogenicity of a single 15-mu g or 90-mu g dose of A/H5N1/Indonesia/05/05 (clade 2) vaccine in adults who were previously primed with A/H5N1/Vietnam/1203/2004 (clade 1) vaccine. High-dose vaccine resulted in significantly higher titers to both clade 1 and 2 antigens. Clade 2 titers were unaffected by the previous dose of clade 1 vaccine. Low-dose priming with a mismatched pandemic influenza A(H5N1) vaccine would improve the rapidity, magnitude, and cross-reactivity of the immunological response following a single high-dose, unadjuvanted, pandemic vaccine.

引用

页码：525 / 530

页数：6

共 50 条

[31] Protection Against a Challenge of Local Isolate H5N1 in Chickens Vaccinated with Inactivated H5N1+H9N2 Influenza Vaccine
Satra, J.
Chanthaworn, T.
Trakarnrungsee, S.
Thaopech, W.
Chaising, A.
15TH CONGRESS OF THE FEDERATION OF ASIAN VETERINARY ASSOCIATIONS, FAVA-OIE JOINT SYMPOSIUM ON EMERGING DISEASES, PROCEEDINGS, 2008, : P125 - P127
[32] Avian Influenza A H5N1 Virus
Loeffelholz, Michael J.
CLINICS IN LABORATORY MEDICINE, 2010, 30 (01) : 1 - +
[33] Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults
Nolan, Terry M.
Richmond, Peter C.
Skeljo, Maryanne V.
Pearce, Georgina
Hartel, Gunter
Formica, Neil T.
Hoschler, Katja
Bennet, Jillian
Ryan, David
Papanaoum, Kelly
Basser, Russell L.
Zambon, Maria C.
VACCINE, 2008, 26 (33) : 4160 - 4167
[34] Efficacy of inactivated vaccine against H5N1 influenza virus infection in mice with type 1 diabetes
Wu, J.
Zhang, F.
Fang, F.
Chang, H.
Wang, F.
Yang, Z.
Sun, B.
Chen, Z.
VACCINE, 2010, 28 (15) : 2775 - 2781
[35] Safety and immunogenicity of an MF59®-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly
Vesikari, Timo
Forsten, Aino
Herbinger, Karl-Heinz
Della Cioppa, Giovanni
Beygo, Jenny
Borkowski, Astrid
Groth, Nicola
Bennati, Mariaviviana
von Sonnenburg, Frank
VACCINE, 2012, 30 (07) : 1388 - 1396
[36] Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity
de Vries, J. J. C.
Bungener, L.
ter Veer, W.
van Alphen, L.
van der Ley, R.
Wilschut, J.
Huckriede, A.
VACCINE, 2009, 27 (06) : 947 - 955
[37] Immunogenicity and Cross-Protective Efficacy Induced by an Inactivated Recombinant Avian Influenza A/H5N1 (Clade 2.3.4.4b) Vaccine against Co-Circulating Influenza A/H5Nx Viruses
Mahmoud, Sara H.
Khalil, Ahmed A.
Abo Shama, Noura M.
El Sayed, Marwa F.
Soliman, Reem A.
Hagag, Naglaa M.
Yehia, Nahed
Naguib, Mahmoud M.
Arafa, Abdel-Sattar
Ali, Mohamed A.
El-Safty, Mounir M.
Mostafa, Ahmed
VACCINES, 2023, 11 (09)
[38] How Low Is the Risk of Influenza A(H5N1) Infection?
Morens, David M.
Taubenberger, Jeffery K.
JOURNAL OF INFECTIOUS DISEASES, 2015, 211 (09) : 1364 - 1366
[39] Safety and immunogenicity of influenza A(H5N1) vaccine stored up to twelve years in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS)
Oshansky, Christine M.
Zhou, James
Gao, Yonghong
Schweinle, Jo Ellen
Biscardi, Karen
DeBeauchamp, Jennifer
Pavetto, Corrina
Wollish, Amy
Webby, Richard J.
Cioce, Vittoria
Donis, Ruben O.
Bright, Rick A.
Armstrong, Kimberly
Gibson, Laura
Hylton, Penny
Jackson, Angela
King, James
Little, James
O'Hara, Michael
Robinson-Wright, Katina
Tresnjak-Smith, Silvija
Walker, Robert
Yeh, Bai
Yeskey, Debra
VACCINE, 2019, 37 (03) : 435 - 443
[40] A/H5N1 Prepandemic Influenza Vaccine (Vepacel®): A Guide to Its Use
Gillian M. Keating
Greg L. Plosker
Katherine A. Lyseng-Williamson
BioDrugs, 2012, 26 (6) : 425 - 430

← 1 2 3 4 5 →